Johns Hopkins Medicine: Study Sets New Standard for Graft-Versus-Host Disease Prevention After Stem Cell Transplant
June 23, 2023
June 23, 2023
BALTIMORE, Maryland, June 23 (TNSjou) -- Johns Hopkins Medicine issued the following news release:
Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published June 22 in the New England Journal of Medicine. The new standard is more effective at preventing GVHD and came with less side effects, compared with the current gold standard.
"Th . . .
Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published June 22 in the New England Journal of Medicine. The new standard is more effective at preventing GVHD and came with less side effects, compared with the current gold standard.
"Th . . .